Beximco Pharmaceuticals Ltd (LON:BXP) (Dhaka:BXPH.DH), a pharmaceutical company in Bangladesh, will start selling a generic version of Merck & Co's (NYSE:MRK) antiviral pill for COVID-19 following local regulatory approval, Reuters news agency reported on Tuesday.
The company stated that it will soon begin selling generic molnupiravir, a cheaper version of Merck's branded pill, in Bangladesh, as it had received emergency use authorisation for the treatment from the country's Directorate General of Drug Administration.
This marks the launch of the world's first generic version of Merck and Ridgeback Biotherapeutics' tablet, molnupiravir.
Molnupiravir had received its first regulatory approval globally, in the UK last week. It is still under review in the United States and Europe.
Beximco added that exports would depend on regulatory approvals globally.
ANI Pharmaceuticals Receives FDA Approval and Imminent Launch of Rifabutin Capsules USP
European Commission Expands Indication for Veklury for the Treatment of Adults
Crescita Signs Exclusive Eight-Country Licensing Agreement with Egis Pharmaceuticals for Pliaglis
Dr. Reddy's Laboratories Launches Valsartan Tablets, USP in the US Market
Dr. Reddy's Laboratories unveils Valsartan Tablets, USP in the US Market
Teva Launches an Authorized Generic of Epiduo Forte Gel in the US
Avacta Gains FDA Approval of its Investigational New Drug Application for AVA6000
Essential Pharma completes two deals with Rosemont Pharmaceuticals
Padagis launches AB-rated generic version of Zomig Nasal Spray